Efficacy and Safety of Intravenous Iron Sucrose in Patients With Hip Fracture to Prevent Perioperative Anemia

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of intravenous iron sucrose in patients with hip fracture and surgical intervention to prevent perioperative anemia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Clinic of Barcelona
• Treatments: Ferric Compounds; Ferric Oxide, Saccharated; Iron

Criteria

Inclusion Criteria:

• Age >= 65 years old

• With Hip fracture or peritrochanteric fracture.

• Who needs surgical intervention.

• And sign the informed consent form.

Exclusion Criteria:

• Tumor pathological fracture.

• Two or more long bone fractures.

• Seric Ferritin levels > 300 ng/ml.

• Hypersensitivity to Iron sucrose or any component of the formulation.

• Patients with allogeneic transfusion rejection.

• Patients with previous blood transfusion request (Hb< 8g/dl).

• Patients treated with hematopoietic growth factors.

• Patients with Anticoagulant treatment, due to thromboembolic high risk disease.

• Asthma in treatment.

• Cirrhosis, Acute Hepatitis, or increased Aminotransferases (> 3 times the upper limit of normal).

• Advanced Dementia (GDS>5) from the Global Deterioration Scale.